Welcome to our dedicated page for Virax Biolabs Group SEC filings (Ticker: VRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Virax Biolabs Group Limited filings document a foreign private issuer developing immunology research and diagnostic technologies, including disclosures tied to the ViraxImmune platform and immune-profiling strategy. Form 6-K reports include shareholder letters, investor presentation exhibits, clinical and commercial framework updates, and statements on the company’s ordinary shares.
The filing record also covers capital-structure matters such as private placements, pre-funded warrants, preferred investment options and ordinary-share issuance. Governance disclosures include annual general meeting notices, proxy materials, shareholder voting and quorum matters, auditor ratification, director elections, board committee appointments, equity incentive plans, and amendments to memorandum and articles of association.
Virax Biolabs Group Limited has filed a Form F-3 to register for resale up to 1,682,360 ordinary shares issuable upon exercise of outstanding warrants. These include 1,644,000 New Warrant Shares with a $6.00 exercise price and 38,360 Placement Agent Warrant Shares with a $7.50 exercise price. The company will not receive proceeds from share resales but may receive cash proceeds if the warrants are exercised, which it intends to use for working capital and general corporate purposes.
The warrants only become exercisable after shareholders approve an Authorized Share Increase to expand capital from 2,000,000 to 500,000,000 ordinary shares; approval is uncertain and, without it, the warrants remain unexercisable. Ordinary shares outstanding were 796,988 as of July 24, 2026. Virax recently completed a warrant inducement transaction that generated approximately $3.3 million in gross proceeds and issued new Series A and B preferred investment options. The company remains an emerging growth company and a foreign private issuer, using reduced U.S. reporting requirements.
Virax Biolabs Group Limited published a shareholder update summarizing audited fiscal 2026 results and recent developments. As of March 31, 2026, it reported $6.4 million in cash, $8.3 million in total assets, $1.0 million in total liabilities and $7.3 million in shareholders’ equity attributable to ordinary shareholders. Research and development expenses were $3.7 million versus $2.0 million in fiscal 2025, general and administrative expenses fell to $2.7 million from $4.0 million, and net loss narrowed to $5.0 million from $6.1 million. Subsequent to year-end, Virax raised approximately $3.3 million in gross proceeds from the exercise of preferred investment options.
The company highlighted a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use-only products across six Southeast Asian markets. Following a 1-for-25 share consolidation, Nasdaq confirmed Virax regained compliance with the minimum bid price requirement. Management also noted that, at a closing price of $3.74 on July 14, 2026, public market valuation was below audited cash and shareholders’ equity despite the recent financing and commercial progress.
Virax Biolabs Group Limited entered into an inducement agreement with a warrant holder, who exercised preferred investment options and warrants to purchase an aggregate of 548,000 Ordinary Shares at a reduced exercise price of $6.00 per share, generating approximately $3.3 million in gross proceeds.
In exchange, Virax issued new unregistered Series A preferred investment options to purchase up to 548,000 Ordinary Shares and short-term Series B preferred investment options to purchase up to 1,096,000 Ordinary Shares, each with a $6.00 exercise price. Both series become exercisable after shareholder approval of an increase in authorized Ordinary Shares and expire five years or eighteen months, respectively, after the later of the resale registration’s effectiveness and that approval.
Virax engaged H.C. Wainwright & Co. as exclusive placement agent, paying a 7.0% cash fee, a 1.0% management fee on gross proceeds, and up to $85,000 of expenses, and issued a placement agent warrant for up to 38,360 Ordinary Shares at $7.50 per share. The company agreed to file a resale registration for the New Warrant Shares, seek shareholder approval for the authorized share increase within 90 days, observe specified lock-up and no-variable-rate covenants, and structured the New Warrants and placement agent warrant as unregistered offerings under Section 4(a)(2) of the Securities Act.
Virax Biolabs Group Limited reported that its wholly owned UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling product line. The deal initially covers six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia.
The agreement allows immediate product supply under purchase orders, creating near-term commercial opportunities and a framework for phased expansion into additional products, higher-volume supply and potential OEM or private-label arrangements. ImmuneSelect is distinct from Virax’s in-development ViraxImmune diagnostic platform, giving the company a separate commercial path alongside its ongoing clinical and regulatory programs.
Virax Biolabs Group Limited reports continued operating losses and outlines extensive business and regulatory risks in its annual report for the year ended March 31, 2026. The company is a development-stage biotechnology firm focused on its ViraxImmune™ T cell diagnostics platform.
Virax recorded net losses of $5,032,184 in 2026, $6,067,232 in 2025 and $6,739,120 in 2024, with an accumulated deficit of $29,612,994 as of March 31, 2026. It highlights dependence on successful regulatory approvals, commercialization of T cell in-vitro diagnostics, protection of intellectual property without patents, and compliance with complex global data protection and medical device rules.
Virax Biolabs Group Limited is implementing a 1-for-25 share consolidation of its authorized, issued and outstanding ordinary shares, effective June 26, 2026. Each block of twenty-five US$0.001 par value shares will be combined into one share with a par value of US$0.025.
Following the consolidation, Virax’s ordinary shares will trade on the Nasdaq Capital Market on a post-consolidation basis under the same symbol "VRAX" but with a new CUSIP number G9495L133. The stated objective is to regain compliance with Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of at least $1 per share, and thereby maintain the company’s Nasdaq listing.
Virax Biolabs Group Limited reported results of its Extraordinary General/Annual Meeting held in June 2026 after an initial attempt lacked a quorum. Only 3.6% of the 19,923,432 ordinary shares entitled to vote were present at the initial meeting, below the one‑third quorum requirement, so the meeting was adjourned.
At the reconvened meeting on June 12, shareholders present or by proxy representing 3.65% of outstanding voting shares formed a quorum under the Articles’ adjourned‑meeting rule. Shareholders approved a share consolidation of ordinary shares on a range of one new share for every 10 to 30 existing shares, with par value per share increasing to $0.01–$0.30 accordingly.
They also approved a fourth amended and restated memorandum and articles of association to reflect the revised authorized share capital, effective from the consolidation date. The share consolidation resolution received 517,694 votes for, 202,763 against and 5,951 abstentions. The new governing documents resolution received 513,758 votes for, 175,512 against and 37,138 abstentions.
Virax Biolabs Group Limited reported early pilot performance data for ViraxImmune™, a blood-based test in development for Long COVID, ME/CFS and related post-acute infection syndromes. In the pilot dataset, the test showed measurable separation between PAIS patients and healthy controls, with 88% specificity and 92% positive predictive value.
ViraxImmune™ has been evaluated in more than 120 subjects in an ongoing UK clinical study. Virax plans a larger clinical validation using samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027, supporting a planned U.S. market-entry via a PAIS-focused Laboratory Developed Test followed by broader in vitro diagnostic development. Virax estimates up to 21 million U.S. adults may be living with Long COVID and related PAIS conditions, with about 2.5 million new cases each year.
Virax Biolabs Group Limited is calling an extraordinary general meeting on June 5, 2026 to seek shareholder approval for a significant share consolidation and related charter changes. The Board proposes consolidating authorized, issued and outstanding ordinary shares at a ratio between 10‑for‑1 and 30‑for‑1, with the exact ratio to be set later and effective on or before July 11, 2026, and fractional entitlements rounded up to the nearest whole share.
The consolidation is intended to help Virax regain compliance with Nasdaq’s Minimum Bid Price Rule, which requires a minimum closing bid of $1.00 per share after the company received deficiency notices and an extension to July 11, 2026. Shareholders will also vote on adopting a fourth amended and restated memorandum and articles of association reflecting the consolidation, plus an adjournment proposal that would allow additional time to solicit proxies if needed. The record date for voting is May 18, 2026, with one vote per ordinary share and a quorum requirement of at least one‑third of voting shares.
Armistice Capital, LLC and Steven Boyd filed an amendment to Schedule 13G disclosing beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited, representing 4.99% of the class.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares, and that Armistice exercises shared voting and dispositive power over the reported securities. The amendment is signed by Steven Boyd on 05/15/2026.